Heinrich Schliemann read Homer’s Iliad and believed in the story of Troy. He was a successful businessman in the United States, cornering the market in indigo dye. He first traveled to China and Japan in 1865 after his lucrative career in the dye business. Subsequently, he found the Troy site while visiting sites in Greece, where he established himself as a pioneer in the field of archeology 6 years after traveling through Eastern countries. If he could have read the old literature “Kai Bao Ben Cao” and believed in the importance of the indigo dye for ulcerative colitis (UC), he would have become a pioneer in the field of medicine. Or, in the present, we might be the second Schliemann in the field of UC.
The aryl hydrocarbon receptor (AhR) is a ligand-activated transcription factor that provides a response for toxic effects, such as dioxin. Recently, specific dietary compounds present in vegetables and metabolites digested by microbes act as the AhR ligand, and they promote intestine immune homeostasis through AhR signaling [1-4]. AhR is expressed by several kinds of immune cells [5-10], epithelial cells [11], and neurons [12] in the intestine. AhR enters the nucleus by binding to its ligand and forms a heterodimer with the AhR nuclear translocator, which binds to the xenobiotic response element on DNA and triggers the transcriptional activation of target genes, such as drug-metabolizing enzymes [9,13].
UC is a chronic intestinal disease, which has increased worldwide over the last few decades, especially in Asia [14,15]. Western drugs, such as anti-tumor necrosis factor α and anti-IL-12/23 p40 antibody that provide systemic immunity, are currently used for UC [16-22]. However, the old Chinese literature “Kai Bao Ben Cao” reported that an indigo compound was used for patients who expressed chronic blood stools around 900 AD.
Because we believed in the literature of the past like Schliemann, and Suzuki et al. [23] reported the retrospective study about the efficacy of indigo naturalis (IN), which mainly contains AhR ligands, on patients with UC in Japan, we conducted prospective clinical trial of IN for them [24], followed by a randomized controlled trial (INDIGO study) [25]. As a result, we demonstrated that 8 weeks of IN is safe and effective in patients with UC, even if in treatment refractory patients [25,26]. Recent Western technologies revealed that AhR ligands lead to innovative treatments that promote the regeneration of mucosal epithelial cells [27,28]. Of note, IN causes adverse effects, such as headaches, gastrointestinal symptoms, mild liver dysfunction, nonspecific enteritis, bowel intussusception, and pulmonary arterial hypertension [29-31]. As a consequence, inspired by the anti-colitic effect of the AhR ligand, both clinical and basic research studies on the efficacy and safety of IN are being conducted [24,32-34]. Based on these verifications, we are preparing a consensus statement on the appropriate use of IN based on the fact-finding survey, while developing indigo containing capsule that disintegrates in the large intestine for the clinical trial (first in human) in order to reduce side effects because indigo is extracted as the active ingredient of IN [34] and is assumed to be absorbed in the small intestine due to its insolubility.
Safe AhR ligand-based drugs will become a novel treatment strategy for inflammatory bowel diseases in the near future. Although the precise mechanism is still unknown, new technology will illuminate the truth in the ancient documents.
Funding Source
The authors received no financial support for the research, authorship, and/or publication of this article.
Conflict of Interest
No potential conflict of interest relevant to this article was reported.
Data Availability Statement
Not applicable.
Author Contributions
Conceptualization: all authors. Project administration: Kanai T. Resources: all authors. Software: Yoshimatsu Y. Supervision: Sujino T. Validation: Kanai T. Writing original draft: Yoshimatsu Y. Writing review & editing: Sujino T, Kanai T. Approval of final manuscript: all authors.
REFERENCESLamasBRichardMLLeducqVCARD9 impacts colitis by altering gut microbiota metabolism of tryptophan into aryl hydrocarbon receptor ligands201622598605GoettelJAGandhiRKenisonJEAHR activation is protective against colitis driven by T cells in humanized mice20161713181329KimYHKwonHSKimDH3,3’-diindolylmethane attenuates colonic inflammation and tumorigenesis in mice20091511641173SugimotoSNaganumaMKanaiTIndole compounds may be promising medicines for ulcerative colitis201651853861QiuJHellerJJGuoXThe aryl hydrocarbon receptor regulates gut immunity through modulation of innate lymphoid cells20123692104Gutiérrez-VázquezCQuintanaFJRegulation of the immune response by the aryl hydrocarbon receptor2018481933QuintanaFJBassoASIglesiasAHControl of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor20084536571YeJQiuJBostickJWThe aryl hydrocarbon receptor preferentially marks and promotes gut regulatory T cells20172122772290StockingerBDi MeglioPGialitakisMDuarteJHThe aryl hydrocarbon receptor: multitasking in the immune system201432403432QuintanaFJMurugaiyanGFarezMFAn endogenous aryl hydrocarbon receptor ligand acts on dendritic cells and T cells to suppress experimental autoimmune encephalomyelitis20101072076820773SchieringCWincentEMetidjiAFeedback control of AHR signalling regulates intestinal immunity2017542242245ObataYCastañoÁBoeingSNeuronal programming by microbiota regulates intestinal physiology2020578284289RothhammerVQuintanaFJThe aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease201919184197MurakamiYNishiwakiYObaMSEstimated prevalence of ulcerative colitis and Crohn’s disease in Japan in 2014: an analysis of a nationwide survey20195410701077AnanthakrishnanANKaplanGGNgSCChanging global epidemiology of inflammatory bowel diseases: sustaining health care delivery into the 21st century20201812521260FukudaTNaganumaMKanaiTCurrent new challenges in the management of ulcerative colitis2019173644LeeSHKwonJEChoMLImmunological pathogenesis of inflammatory bowel disease2018162642OhSJShinGYSohHLong-term outcomes of infliximab in a real-world multicenter cohort of patients with acute severe ulcerative colitis202119323331NakamuraSAsanoTTsuchiyaHReal-world data for golimumab treatment in patients with ulcerative colitis in Japan: interim analysis in post-marketing surveillance202220329341OgataHHagiwaraTKawaberiTKobayashiMHibiTSafety and effectiveness of adalimumab in the treatment of ulcerative colitis: results from a large-scale, prospective, multicenter, observational study202119419429ShinSYParkSJKimYClinical outcomes and predictors of response for adalimumab in patients with moderately to severely active ulcerative colitis: a KASID prospective multicenter cohort study202220350360HisamatsuTKimHJMotoyaSEfficacy and safety of ustekinumab in East Asian patients with moderately to severely active ulcerative colitis: a subpopulation analysis of global phase 3 induction and maintenance studies (UNIFI)202119386397SuzukiHKanekoTMizokamiYTherapeutic efficacy of the Qing Dai in patients with intractable ulcerative colitis20131927182722SugimotoSNaganumaMKiyoharaHClinical efficacy and safety of oral Qing-Dai in patients with ulcerative colitis: a single-center open-label prospective study201693193201NaganumaMSugimotoSMitsuyamaKEfficacy of indigo naturalis in a multicenter randomized controlled trial of patients with ulcerative colitis2018154935947NaganumaMSugimotoSFukudaTIndigo naturalis is effective even in treatment-refractory patients with ulcerative colitis: a post hoc analysis from the INDIGO study202055169180MetidjiAOmenettiSCrottaSThe environmental sensor AHR protects from inflammatory damage by maintaining intestinal stem cell homeostasis and barrier integrity201849353362StockingerBShahKWincentEAHR in the intestinal microenvironment: safeguarding barrier function202118559570NaganumaMSugimotoSSuzukiHAdverse events in patients with ulcerative colitis treated with indigo naturalis: a Japanese nationwide survey201954891896HiraideTTerataniTUemuraSPulmonary arterial hypertension caused by AhR signal activation protecting against colitis2021203385388MasakiTOkazawaMAsanoRAryl hydrocarbon receptor is essential for the pathogenesis of pulmonary arterial hypertension2021118e2023899118YoshimatsuYNaganumaMSugimotoSDevelopment of an indigo naturalis suppository for topical induction therapy in patients with ulcerative colitis2020101492498SunZLiJDaiYIndigo naturalis alleviates dextran sulfate sodium-induced colitis in rats via altering gut microbiota202011731KawaiSIijimaHShinzakiSIndigo naturalis ameliorates murine dextran sodium sulfate-induced colitis via aryl hydrocarbon receptor activation201752904919